Achieve Life Sciences Promotes Jaime Xinos to CCO for Cytisinicline Launch
Achieve Life Sciences Announces Leadership Promotion
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a pioneering company in the late-stage pharmaceutical sector, is excited to announce that Jaime Xinos has been promoted to Chief Commercial Officer. This strategic move aims to enhance the company's commercial readiness for the launch of its groundbreaking product, cytisinicline, aimed at combating nicotine addiction.
The Journey of Jaime Xinos
Joining Achieve Life Sciences in 2017 as the Executive Vice President of Commercial, Ms. Xinos has made significant contributions during her tenure. In her new capacity, she will not only oversee the day-to-day commercial operations but also spearhead the strategic preparations for the anticipated U.S. launch of cytisinicline. Key to her role will be the engagement with vital stakeholders, including patients, healthcare professionals, and payors. This coordinated effort is crucial for ensuring a successful product introduction following FDA approval.
CEO's Vision
Rick Stewart, CEO of Achieve Life Sciences, expressed his enthusiasm for Xinos’ promotion, emphasizing her leadership in the commercial sector. He stated that her innovative, patient-centered strategies will be pivotal as they get ready to introduce cytisinicline to the market. The company is dedicated to providing new hope to millions battling nicotine addictions who are in search of effective solutions.
Strategic Partnerships and Collaborations
Under Ms. Xinos’ guidance, Achieve plans to establish strategic partnerships with experienced commercialization experts. With a focus on small biotech challenges, the goal is to develop efficient, value-driven solutions that will aid in successful market entry for cytisinicline. Her extensive experience in building collaborations will play a significant role in this aspect.
Commitment to Public Health
Reflecting on her new position, Ms. Xinos stated, "I am honored to take on this significant role during such an important time for Achieve Life Sciences. Cytisinicline represents a remarkable opportunity to become the first new FDA-approved treatment for nicotine dependence in almost two decades. My priority will be establishing strong partnerships and implementing innovative strategies that enhance patient care and drive value for our stakeholders."
Experience and Expertise
With nearly 25 years of experience in the biotechnology and pharmaceutical sectors, Ms. Xinos has held various significant roles at major companies like OncoGenex, Pfizer, Novartis, and Abbott Laboratories. Recognized as a thought leader, she excels at turning scientific discoveries into commercial opportunities. She holds both a Bachelor of Arts and an MBA from the University of Illinois, adding strong academic credentials to her wealth of practical knowledge.
Addressing a Global Epidemic
Achieve Life Sciences is committed to tackling the global nicotine addiction issue, which affects around 29 million adults in the U.S. alone. Tobacco use remains the leading cause of preventable deaths, contributing to over eight million fatalities worldwide each year. With a staggering percentage of lung cancer deaths and cardiovascular-related deaths linked to smoking and secondhand smoke, the need for effective treatments is pressing.
Moreover, the rise of vaping among over 11 million adults and the increasing use among adolescents (approximately 1.6 million reported e-cigarette users in high school and middle school) highlight the urgent demand for effective cessation aids. Current offerings have not yet included FDA-approved treatments specifically designed for e-cigarette cessation.
Innovative Approach with Cytisinicline
Cytisinicline is derived from natural plant sources and holds promise due to its strong binding affinity to nicotine receptors in the brain. This investigational drug aims to help individuals reduce cravings and manage withdrawal symptoms effectively. Although still awaiting FDA approval, cytisinicline could significantly change the landscape of nicotine dependence treatment.
Frequently Asked Questions
What is Achieve Life Sciences focused on?
The company is dedicated to developing and commercializing cytisinicline for nicotine addiction treatment.
Who has been promoted at Achieve Life Sciences?
Jaime Xinos has been promoted to Chief Commercial Officer.
What role will Jaime Xinos play at Achieve Life Sciences?
She will oversee all commercial operations and prepare for the launch of cytisinicline.
How does cytisinicline work?
Cytisinicline aims to reduce cravings and withdrawal symptoms by interacting with nicotine receptors in the brain.
What is the significance of this promotion?
This role is crucial as Achieve prepares for a successful market entry for cytisinicline after FDA approval.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Insight into Recent Trading Patterns Around Sea Limited
- F.N.B. Corporation Celebrates National Awards for Work Culture
- KeyShot Unveils Innovative Tools for Product Development
- TNT Sports Launches Exciting Partnership with Unrivaled League
- Clarion Communications Expands Market Reach with IPitomy Deal
- IRG Executive Team Bolstered with Key Promotions to Drive Growth
- Penumbra Stock Target Boosted: Analysts Eye Growth and Earnings
- Southern Company Stock Reaches New Heights, Driven by Growth
- CME Group Reaches New Heights: An Investor's Perspective
- H.C. Wainwright Adjusts Target for Inventiva Amid Changes
Recent Articles
- General Motors Backs Lithium Americas with $625 Million Investment
- Indico Data Launches Pioneering AI Solution for Insurance Underwriting
- Morgan Stanley and United Airlines See Gains Ahead of Market Open
- FTC's New 'Click to Cancel' Rule to Ease Subscription Cancellations
- Forge Nano Secures $10M from GM Ventures for Battery Innovation
- Spire Inc. Plans Year-End Earnings Call Scheduled Soon
- Abbott Reports Strong Sales Growth in Medical Devices for 2024
- Rexel Faces Market Challenges as Q3 Sales Decline Significantly
- Hyundai Mobis Expands European Footprint with New Plant
- Exciting Overview of the 2025 NAMM Show Schedule & Events
- Analyzing Key Indicators of the Current Economic Landscape
- U.S. Army's Cloud Transformation: Enhancing HR and Efficiency
- Discover the Innovative TCL LINKPORT IK511 Device at T-Mobile
- Arcadia Unveils Cutting-Edge Interoperability Innovations
- REI Systems Seals $4M Deal to Modernize NY Education Grants
- Sesame Expands Access to Compounded Semaglutide Nationwide
- Discover Korean Heritage Through Captivating Video Journey
- Innovative Steps by Frontline Education for K-12 Management
- Exploring the Booming Hydrogen Trucks Market: Future Insights
- DZS Transitions WiFi Management to AXON Networks in Major Deal
- Aquafeed Market Forecast Shows Significant Growth Potential
- Fluid Sensors Market Expected to Reach $27.65 Billion Growth
- Brink's Announces Upcoming Third-Quarter Earnings Call Details
- 23andMe's Recent Reverse Stock Split: Impact and Insights
- Service Properties Trust's Strategic Moves for Financial Growth
- Color Health Enhances Virtual Cancer Clinic with Expanded Services
- Ocean Power Technologies Showcases Innovative USV at ADIPEC
- Enhancements in Arcadia's Healthcare Data Solutions Announced
- Arq, Inc. to Discuss Q3 2024 Results in Upcoming Call
- ISC Plans to Announce 2024 Q3 Financial Performance Soon
- Breakthrough for Theriva Biologics in Pediatric Cancer Treatment
- Morgan Stanley's Q3 Performance: Strong Earnings and Client Growth
- Gentherm CEO Set for Keynote at Baird Global Conference
- Tonix Pharmaceuticals Pushes Forward with Fibromyalgia Drug Approval
- Corbus Completes Enrollment for CRB-701 Clinical Trial Stage
- Bitdeer Drives Innovation in Bitcoin Mining with SEAL02 Chip
- Office Properties Income Trust Declares Latest Dividend Payout
- Phunware Drives Innovation with New AI-Enhanced Platform
- Shift to Online Shopping Trends: Insights from 1WorldSync Report
- Jason L. Mitchell Joins Adverum Biotechnologies as CCO
- Vita Coco Gears Up for Q3 2024 Financial Results Announcement
- Understanding 5.6 Million Vacant Homes and Housing Trends in America
- Latest Insights on RMR Group's Dividend Announcement and Strategy
- Achieve Life Sciences Names Jaime Xinos New Chief Commercial Officer
- AXON Networks Enhances Portfolio with DZS Software Acquisition
- Ribbon Communications Recognized for Sustainability Success
- Chatham Park Shines Bright with Awards at Esteemed Event
- Brink’s Company Preparing for Upcoming Earnings Call
- Prosperity Asset Management Welcomes New Leaders to Drive Growth
- Nykredit Realkredit Adjusts Coupon Rates for Floating Bonds